Bioventus (NSDQ:BVS) announced today that it received FDA 510(k) clearance for its neXus BoneScalpel Access handpiece.
Durham, North Carolina-based Bioventus said in a news release that the neXus ultrasonic surgical aspirator system — a next-generation integrated ultrasonic surgical platform driven by a proprietary digital algorithm — powers the BoneScalpel Access device.
The neXus system combines all features of soft and hard tissue removal in a single, fully integrated offering, Bioventus said. Its indications under FDA 510(k) clearance include use in the fragmentation and aspiration of soft and hard tissue in neurosurgery, gastrointestinal and affiliated organ surgery, urological surgery, plastic and reconstructive surgery, general surgery, orthopedic surgery, gynecology and more.
Bioventus plans to launch BoneScalpel Access — a product the company picked up through its recent acquisition of Misonix — in 2022. The neXus ultrasonic surgical aspirator s…